商品名：Panoquell-CA1 (Ceva)
Fuzapladib is a Leukocyte Function-Associated Antigen-1 (LFA-1) activation inhibitor. LFA-1 inhibition prevents inflammatory cell (neutrophil) adhesion and migration into sites of tissue injury. In pancreatitis, this reduces neutrophil extravasation into pancreatic tissue, limiting lesion expansion and preventing complications such as multi-organ failure. First drug conditionally approved for acute canine pancreatitis.
Treatment of clinical signs associated with acute onset of canine pancreatitis (ACP). FDA conditionally approved November 2022.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
主控必須另行接受精確商品、法域、核准狀態、配方、稀釋液、物種、疾病定義、族群、途徑、劑量、時程、監測、共同用藥與安全邊界後，才可考慮任何執行；本 review 本身不啟用任何計算或處方。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。